Alistair J. Roddick
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Estimating the long-term effects of aspirin for primary prevention.
Journal: European heart journal
Published: September 09, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.
Journal: The lancet. Diabetes & endocrinology
Published: May 09, 2025
Plain language summary of a study looking at the effect of empagliflozin treatment in patients with chronic kidney disease.
Journal: Clinical kidney journal
Published: February 27, 2024
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.
Journal: BMC nephrology
Published: April 25, 2023
Safety and pharmacokinetic profile of apixaban in end-stage renal disease: A real-world analysis.
Journal: EJHaem
Published: September 29, 2022
Simulated virtual on-call training programme for improving non-specialised junior doctors' confidence in out-of-hours psychiatry: quantitative assessment.
Journal: BJPsych bulletin
Published: September 08, 2022
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials.
Journal: EClinicalMedicine
Published: August 04, 2021
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply.
Journal: JAMA
Published: June 12, 2019
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Journal: JAMA
Published: January 23, 2019
Applying Network Meta-Analysis to Cardiovascular Outcome Trials of Glucose-Lowering Drugs.
Journal: JACC. Heart failure
Published: September 24, 2018
Last Updated: 09/26/2026